Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872438 | 0.89 | EPHX2 (0.61) | MEN1KMT2AEPHX2LTA4H | |
| SCHEMBL4451599 | 0.88 | EPHX2 (0.58) | MAOBKMT2AEPHX2HDAC1 | |
| SCHEMBL23291309 | 0.87 | EPHX2 (0.60) | MAOBEPHX2HDAC1 | |
| SCHEMBL3004957 | 0.86 | FFAR1 (0.55) | MEN1KMT2AEPHX2HDAC1FFAR1 | |
| SCHEMBL23291142 | 0.85 | CA2 (0.49) | MEN1KMT2A | |
| SCHEMBL8591195 | 0.83 | MAPT (0.56) | MEN1KMT2ARXRAHDAC1 | |
| SCHEMBL16822016 | 0.83 | CA2 (0.49) | MEN1KMT2A | |
| SCHEMBL13894612 | 0.82 | FFAR1 (0.46) | MAOBRXRAFFAR1PPARG | |
| SCHEMBL24690271 | 0.82 | CA12 (0.64) | MEN1KMT2A | |
| SCHEMBL13886725 | 0.82 | HDAC8 (0.54) | KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7339079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-04 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-16 | — | — | US | disclosed |
| US-6979750-B1 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050267207-A1 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | TPO, TSHR, THRB | MAOB 124/4885MEN1 179/4885KMT2A 4034/4885 |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | MAOB 131/4885MEN1 185/4885KMT2A 3934/4885 |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | MAOB 124/4885MEN1 179/4885KMT2A 4034/4885 |
| US-20050267207-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | MAOB 131/4885MEN1 185/4885KMT2A 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.